Latest Period
Q4 2025
Security Snapshot
Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) Institutional Ownership
CUSIP: 87975F104
13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026
Institutions Reporting
33
Shares (Excl. Options)
2,285,727
Price
$1.33
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, no par value
- Symbol
- TELO on Nasdaq
- Shares outstanding
- 34,382,284
- Price per share
- $1.30
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 2,285,727
- Total reported value
- $3,040,166
- % of total 13F portfolios
- 0%
- Share change
- -46,337
- Value change
- -$68,478
- Number of holders
- 33
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value is tracked under CUSIP 87975F104.
- 33 institutions reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 33 to 5 between Q4 2025 and Q1 2026.
- Reported value moved from $3,040,166 to $105,510.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 33 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 87975F104?
CUSIP 87975F104 identifies TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87975F104:
Significant Owners of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| DEJORIA JOHN PAUL | 9.4% | +79% | $4,315,850 | +$1,955,233 | 3,245,000 | +83% | John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity | 31 Dec 2025 |
As of 31 Dec 2025, 33 institutional investors reported holding 2,285,727 shares of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO). This represents 6.6% of the company’s total 34,382,284 outstanding shares.
Institutional Holders of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 80,699 | $105,510 | +$9,598 | $1.30 | 5 |
| 2025 Q4 | 2,285,727 | $3,040,166 | -$68,478 | $1.33 | 33 |
| 2025 Q3 | 2,332,205 | $3,240,559 | -$616,944 | $1.39 | 31 |
| 2025 Q2 | 2,807,449 | $3,509,640 | -$1,509,843 | $1.25 | 42 |
| 2025 Q1 | 3,692,775 | $11,927,929 | +$377,557 | $3.23 | 42 |
| 2024 Q4 | 3,563,053 | $14,680,234 | +$6,102,927 | $4.12 | 37 |
| 2024 Q3 | 2,045,931 | $13,136,057 | +$9,006,860 | $6.42 | 33 |
| 2024 Q2 | 361,326 | $1,737,881 | +$1,328,649 | $4.81 | 24 |
| 2024 Q1 | 79,917 | $413,466 | +$413,466 | $5.15 | 7 |